Clinical Trial

Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer

Study acronym: CoLiQ
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
CoLiQ is a clinical study designed to evaluate the clinical usefulness of circulating tumor DNA (ctDNA) markers found in blood, as a liquid biopsy for diagnosis, prognosis and follow-up of colorectal cancer. The main questions it aims to answer are: 1) Can a panel of ctDNA markers identify CRC patients among the other patients summoned for colonoscopy? and 2) Does the type, number and level of ctDNA markers vary with the subtype and clinical course of CRC? Participants will be asked to answer a questionnaire and give a blood sample at inclusion. In addition, patients with CRC will be asked to give an extra test tube at their routine treatment and follow-up blood sampling.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-06.
Status change: Not Yet Recruiting → Recruiting 2025-04-25
Trial Details
NCT Number NCT06307938
Lead Sponsor Helse Nord-Trøndelag HF
Collaborators: Norwegian University of Science and Technology
Conditions Colorectal Cancer, Colorectal Adenoma
Enrollment 3,000 participants
Start Date 2025-03-10
Primary Completion 2026-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2025-04-30